Shuliang Guo

机构：The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing Medical University · ORCID：0000-0003-3572-7421

发表论文 168 篇 · 总被引 2192 次 · h-index 24

代表论文

• Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial (2025 · The Lancet · 被引 40)
• Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study (2025 · The Lancet Respiratory Medicine · 被引 19)
• Association between albumin corrected anion gap and in-hospital mortality in critically ill patients with chronic obstructive pulmonary disease (2025 · Therapeutic Advances in Respiratory Disease · 被引 13)
• Association between systemic immune-inflammation index and mortality in critically ill patients with chronic obstructive pulmonary disease: insights from the MIMIC-IV database (2025 · Frontiers in Medicine · 被引 6)
• Systemic inflammation mediates the relationship between urinary cadmium and chronic cough risk: findings based on multiple statistical models (2025 · BioMetals · 被引 4)
• Blood Glucose Levels, Inflammation, and Mortality in Asthmatic Populations: A Prospective Cohort Study (2025 · Journal of Epidemiology and Global Health · 被引 2)